Roche’s ipatasertib has improved progression-free survival in a sub-group of previously untreated metastatic castration-resistant prostate cancer patients – those whose tumors had PTEN loss – in a Phase III study. However the AKT inhibitor failed to cut the risk of disease worsening or death in the broader population.
Roche's hopes of breaking into the prostate cancer market have been slightly knocked following mixed results from a late-stage trial of ipatasertib, the Swiss major's investigational AKT inhibitor.
The Phase III IPATential150 study is evaluating ipatasertib in combination with Johnson & Johnson's blockbuster Zytiga (abiraterone) and prednisone/prednisolone...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
